Viemed Healthcare US ((VMD)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Viemed Healthcare used its latest earnings call to showcase broad-based momentum despite a few near-term headwinds. Management emphasized strong revenue growth, expanding cash flow and a more diversified business mix, while acknowledging policy-driven pressures in the ventilator segment and seasonal softness. Overall tone was confident, with leadership underscoring improved capital efficiency and reiterating bullish guidance for the year.
Revenue Growth Holding Strong Amid Seasonal Pause
Viemed reported first-quarter revenue of $75.4 million, up 28% from a year earlier, underscoring robust underlying demand. Sequentially, sales were essentially flat versus the prior quarter’s $76.2 million, a pattern executives framed as normal seasonality rather than a sign of slowing growth.
Free Cash Flow Swings Sharply Into Positive Territory
Free cash flow improved to $2.6 million from a negative $5.7 million a year ago, marking an $8.3 million turnaround that investors will welcome. On a trailing twelve-month basis, free cash flow reached $36.3 million, up from $23.3 million through 2025 and just $11.6 million at the end of 2024, signaling a structurally stronger cash engine.
Sleep Business Powers Ahead With PAP Growth
The company’s sleep segment continued to scale, with PAP therapy patients reaching nearly 36,000, a 57% jump year over year and 4% growth sequentially. Resupply patients climbed 47% year over year, deepening a recurring revenue stream that management views as an increasingly predictable and profitable pillar.
Maternal Health Integration Demonstrates Platform Leverage
Management highlighted that the Lehan acquisition remains accretive, providing a launchpad for maternal health expansion. In markets where Lehan previously had no footprint, Viemed serviced just under 4,000 new maternal health patients, underscoring the scalability of its platform and cross-market reach.
Revenue Mix Becomes Broader and Less Vent-Dependent
Ventilator rentals generated $35.4 million, or about 47% of revenue, down from 54% in 2025 as other lines gained share. Other home medical equipment rentals rose 25% to $16.2 million, while equipment and supply sales more than doubled to $17.5 million, lowering concentration risk and bolstering capital efficiency.
Margins and Profitability Show Underlying Improvement
Gross profit came in at $42.8 million, with gross margin edging up to 56.8% from 56.3% a year ago. Adjusted EBITDA reached $14.3 million, or 19% of revenue, and excluding a prior-year gain, management pointed to roughly 200 basis points of margin expansion as evidence of operational leverage.
Operating Cash Flow Rises as CapEx Becomes Leaner
Operating cash flow nearly tripled to $8.1 million from $2.9 million in the prior-year quarter, reflecting tighter working capital and stronger earnings quality. Net capital expenditures fell to $5.5 million from $8.5 million, allowing the company to lower its full-year net CapEx outlook to 9.0%–10.5% of revenue.
Balance Sheet Strengthens With Debt Reduction and Buybacks
Viemed ended the quarter with $9.8 million in cash and $46 million of available credit capacity, while reducing long-term debt to $8.3 million. The company also returned capital to shareholders by repurchasing and canceling 150,000 shares for $1.4 million alongside $3.2 million of principal debt payments.
Ventilation Operations Show Positive Demand Signals
New ventilator setups accelerated, with March starts rising to 759 from 692 a year earlier, roughly a 9.7% increase. Management also noted that compliance among active ventilator patients improved nearly 20% since implementation of the new coverage rules, pointing to healthier long-term utilization.
Ventilator Census Faces Policy-Driven Turnover Pressure
Despite solid setup activity, net ventilator patient census ended the quarter at 12,089 and is under pressure from higher turnover. New compliance evaluation points in the coverage framework mean more patients can fall off service, creating a temporary drag on net census even as demand remains intact.
Seasonal Factors Weigh on Sequential Sleep Trends
The company reiterated that first-quarter revenue is typically flat to slightly down versus the December period, and this year followed that playbook. Sleep resupply patient counts declined sequentially, which management attributed to deductible resets and normal seasonal moderation rather than structural weakness.
Reported Margins Clouded by Prior-Year Gain
Adjusted EBITDA margin was 19% compared with 21.6% in 2025, but management stressed the comparison is distorted by a $2.7 million recurring gain in the prior-year period. Net income was steady at $2.6 million, or $0.06 per share, leaving normalized earnings progress somewhat masked in headline figures.
SG&A Mix Shifts as Company Invests in Growth
Selling, general and administrative costs improved to 46.1% of revenue from 48.1%, delivering a 200 basis-point efficiency gain. However, absolute SG&A dollars increased by $6.4 million, driven largely by employee-related expenses and added headcount from the Lehan acquisition, reflecting continued investment in scaling the business.
Patient Access Risks Under Current Compliance Rules
Management flagged clinical risks tied to the current coverage framework, where temporary noncompliance can cost patients ventilator access. Situations such as illness or caregiver changes can trigger loss of service, prompting the company to continue advocacy efforts aimed at preserving access for vulnerable populations.
Comparability Headwinds From One-Off Items and Seasonality
Executives cautioned that prior-year gains and seasonal patterns complicate year-over-year comparisons in some metrics. These distortions can make reported margins and earnings appear softer, even as underlying operations show clear improvement in growth, efficiency and cash generation.
Guidance Signals Confidence in Multi-Quarter Growth Path
Viemed raised the low end of its full-year net revenue outlook to a range of $312 million to $320 million, while reaffirming adjusted EBITDA guidance of $65 million to $69 million, implying margins near 21% to 22%. Management also tightened CapEx expectations to 9.0%–10.5% of revenue and projected sequential revenue growth of roughly 3%–5% per quarter for the rest of 2026.
Viemed’s earnings call painted a picture of a company leaning into growth while steadily upgrading its financial profile. Robust expansion in sleep and maternal health, improved cash flow, and a stronger balance sheet are offsetting policy and seasonal bumps in ventilation. For investors, the message was one of disciplined execution and sustained confidence in the company’s long-term earnings power.